Our applications for CVD research

Novel biomarkers for cardiovascular disease and metabolic profiling of drug targets

Ideal platform for CVD research

Nightingale’s biomarkers have been shown to predict cardiovascular disease incidence beyond existing risk factors and thus improve the identification of high-risk individuals. Our platform has also been used for detailed metabolic profiling of existing and novel cardiovascular treatments, such as statin therapy and PCSK9 inhibition. This showcases the potential for using Nightingale’s metabolic profiling to evaluate the effectiveness of new therapies, as well as to reveal potential adverse metabolic effects.

Ideal platform for CVD research

Nightingale’s biomarkers have been shown to predict cardiovascular disease incidence beyond existing risk factors and thus improve the identification of high-risk individuals. Our platform has also been used for detailed metabolic profiling of existing and novel cardiovascular treatments, such as statin therapy and PCSK9 inhibition. This showcases the potential for using Nightingale’s metabolic profiling to evaluate the effectiveness of new therapies, as well as to reveal potential adverse metabolic effects.

The next frontiers

As ethnic groups are dramatically different in their risk of cardiovascular diseases, there’s an emerging need for tailored risk assessment tools for different populations. Large population-based studies from diverse ethnicities are required to help identify high-risk individuals and improve public health in different ethnic groups. Large population studies also contribute improving risk algorithms in different age- and gender groups. The combination of genomics, metabolomics and electronic health records data holds tremendous opportunities for researchers.  

Nightingale’s platform is suitable for metabolic profiling of large-scale projects, which are needed to redefine current CVD prediction tools. It has been successfully used for metabolic profiling of large-scale projects like the Mexico City study (150 000 samples) and the UK Biobank study (500 000 samples). 

The next frontiers

As ethnic groups are dramatically different in their risk of cardiovascular diseases, there’s an emerging need for tailored risk assessment tools for different populations. Large population-based studies from diverse ethnicities are required to help identify high-risk individuals and improve public health in different ethnic groups. Large population studies also contribute improving risk algorithms in different age- and gender groups. The combination of genomics, metabolomics and electronic health records data holds tremendous opportunities for researchers.  

Nightingale’s platform is suitable for metabolic profiling of large-scale projects, which are needed to redefine current CVD prediction tools. It has been successfully used for metabolic profiling of large-scale projects like the Mexico City study (150 000 samples) and the UK Biobank study (500 000 samples). 

Related services

Our blood platform contains established biomarkers such as detailed lipid measures, amino acids and fatty acids, enabling novel discoveries and translational research.

Contact

Whether you have a question or you would like to ask for an offer, let us know and we'll get back to you very soon.